FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2464758963> ?p ?o ?g. }

• W2464758963 endingPage "e0004821" @default.
• W2464758963 startingPage "e0004821" @default.
• W2464758963 abstract "A recombinant live attenuated tetravalent dengue vaccine (CYD-TDV) has been shown to be efficacious in preventing virologically-confirmed dengue disease, severe dengue disease and dengue hospitalization in children aged 2-16 years in Asia and Latin America. We analyzed pooled safety data from 18 phase I, II and III clinical trials in which the dengue vaccine was administered to participants aged 2-60 years, including long-term safety follow-up in three efficacy trials. The participants were analyzed according to their age at enrollment. The percentage of participants aged 2-60 years reporting ≥1 solicited injection-site or systemic reactions was slightly higher in the CYD-TDV group than in the placebo group. The most common solicited injection-site reactions were pain. Headache and malaise were the most common solicited systemic reactions. In both groups 0.3% of participants discontinued for safety reasons. The most common unsolicited adverse events were injection-site reactions, gastrointestinal disorders, and infections. Reactogenicity did not increase with successive doses of CYD-TDV. The frequency and nature of SAEs occurring within 28 days of any dose were similar in the CYD-TDV and placebo groups and were common medical conditions that could be expected as a function of age. Baseline dengue virus serostatus did not appear to influence the safety profile. No vaccine-related anaphylactic reactions, neurotropic events or viscerotropic events were reported. In year 3 after dose 1, an imbalance for dengue hospitalization, including for severe dengue, observed in participants aged <9 years in the CYD-TDV group compared with the placebo group was not observed for participants aged ≥9 years. In Year 4, this imbalance in participants aged <9 years was less marked, giving an overall lower risk of dengue hospitalization or severe dengue from dose 1 to Year 4 in the CYD-TDV group. These results have contributed to the definition of the target population for vaccination (≥9 years old) for which CYD-TDV has a satisfactory safety profile. Long-term safety will continue to be monitored in the ongoing follow-up of efficacy trials. Safety and effectiveness in real-life settings will be assessed through post-licensure studies." @default.
• W2464758963 created "2016-07-22" @default.
• W2464758963 creator A5008687261 @default.
• W2464758963 creator A5035976456 @default.
• W2464758963 creator A5044364769 @default.
• W2464758963 creator A5048822204 @default.
• W2464758963 creator A5063513460 @default.
• W2464758963 creator A5075669592 @default.
• W2464758963 creator A5077027716 @default.
• W2464758963 date "2016-07-14" @default.
• W2464758963 modified "2023-10-12" @default.
• W2464758963 title "Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials" @default.
• W2464758963 cites W1017348960 @default.
• W2464758963 cites W1031737100 @default.
• W2464758963 cites W1120017812 @default.
• W2464758963 cites W1143620379 @default.
• W2464758963 cites W1970660384 @default.
• W2464758963 cites W1980444528 @default.
• W2464758963 cites W1989767365 @default.
• W2464758963 cites W1991673588 @default.
• W2464758963 cites W1996416492 @default.
• W2464758963 cites W2003583702 @default.
• W2464758963 cites W2021113575 @default.
• W2464758963 cites W2023010141 @default.
• W2464758963 cites W2027932038 @default.
• W2464758963 cites W2028079124 @default.
• W2464758963 cites W2034093511 @default.
• W2464758963 cites W2036694918 @default.
• W2464758963 cites W2043066204 @default.
• W2464758963 cites W2044886599 @default.
• W2464758963 cites W2048575064 @default.
• W2464758963 cites W2053017525 @default.
• W2464758963 cites W2053490656 @default.
• W2464758963 cites W2058833815 @default.
• W2464758963 cites W2065311998 @default.
• W2464758963 cites W2081020320 @default.
• W2464758963 cites W2086437713 @default.
• W2464758963 cites W2086448648 @default.
• W2464758963 cites W2097288560 @default.
• W2464758963 cites W2099814026 @default.
• W2464758963 cites W2100166387 @default.
• W2464758963 cites W2106800284 @default.
• W2464758963 cites W2116471574 @default.
• W2464758963 cites W2117769971 @default.
• W2464758963 cites W2126789944 @default.
• W2464758963 cites W2130777631 @default.
• W2464758963 cites W2131222241 @default.
• W2464758963 cites W2133598290 @default.
• W2464758963 cites W2150244847 @default.
• W2464758963 cites W2164079841 @default.
• W2464758963 cites W2195096572 @default.
• W2464758963 cites W2317607320 @default.
• W2464758963 cites W2950420258 @default.
• W2464758963 doi "https://doi.org/10.1371/journal.pntd.0004821" @default.
• W2464758963 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4945086" @default.
• W2464758963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27414655" @default.
• W2464758963 hasPublicationYear "2016" @default.
• W2464758963 type Work @default.
• W2464758963 sameAs 2464758963 @default.
• W2464758963 citedByCount "37" @default.
• W2464758963 countsByYear W24647589632016 @default.
• W2464758963 countsByYear W24647589632017 @default.
• W2464758963 countsByYear W24647589632018 @default.
• W2464758963 countsByYear W24647589632019 @default.
• W2464758963 countsByYear W24647589632020 @default.
• W2464758963 countsByYear W24647589632021 @default.
• W2464758963 countsByYear W24647589632022 @default.
• W2464758963 countsByYear W24647589632023 @default.
• W2464758963 crossrefType "journal-article" @default.
• W2464758963 hasAuthorship W2464758963A5008687261 @default.
• W2464758963 hasAuthorship W2464758963A5035976456 @default.
• W2464758963 hasAuthorship W2464758963A5044364769 @default.
• W2464758963 hasAuthorship W2464758963A5048822204 @default.
• W2464758963 hasAuthorship W2464758963A5063513460 @default.
• W2464758963 hasAuthorship W2464758963A5075669592 @default.
• W2464758963 hasAuthorship W2464758963A5077027716 @default.
• W2464758963 hasBestOaLocation W24647589631 @default.
• W2464758963 hasConcept C126322002 @default.
• W2464758963 hasConcept C142724271 @default.
• W2464758963 hasConcept C197934379 @default.
• W2464758963 hasConcept C203014093 @default.
• W2464758963 hasConcept C204787440 @default.
• W2464758963 hasConcept C27081682 @default.
• W2464758963 hasConcept C2777704310 @default.
• W2464758963 hasConcept C2779308166 @default.
• W2464758963 hasConcept C2779635636 @default.
• W2464758963 hasConcept C2780868878 @default.
• W2464758963 hasConcept C533803919 @default.
• W2464758963 hasConcept C535046627 @default.
• W2464758963 hasConcept C71924100 @default.
• W2464758963 hasConcept C8891405 @default.
• W2464758963 hasConceptScore W2464758963C126322002 @default.
• W2464758963 hasConceptScore W2464758963C142724271 @default.
• W2464758963 hasConceptScore W2464758963C197934379 @default.
• W2464758963 hasConceptScore W2464758963C203014093 @default.
• W2464758963 hasConceptScore W2464758963C204787440 @default.
• W2464758963 hasConceptScore W2464758963C27081682 @default.
• W2464758963 hasConceptScore W2464758963C2777704310 @default.

• next